博济医药(300404) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥126,422,508.85, representing a year-on-year increase of 22.31% compared to ¥103,364,118.12 in the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥5,403,577.08, a decrease of 16.78% from ¥6,511,452.33 in Q3 2022[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,930,576.10, down 15.33% from ¥4,660,922.91 in the same period last year[5]. - The basic earnings per share for Q3 2023 were ¥0.0146, down 17.05% from ¥0.0177 in the same period last year[5]. - The company reported a total comprehensive income of ¥25,970,648.33, slightly down from ¥26,487,744.63 in the previous year[32]. - Net profit for the quarter was ¥24,847,179.31, representing a 10.3% increase from ¥22,389,514.08 year-over-year[31]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of ¥2,512,208.95, a significant decline of 131.64% compared to a net inflow of ¥7,941,003.79 in the previous year[5]. - Cash flow from operating activities showed a net outflow of ¥2,512,208.95, a decline from a net inflow of ¥7,941,003.79 in the previous period[33]. - Cash flow from investing activities resulted in a net outflow of ¥189,689,242.87, compared to a net outflow of ¥248,926,086.78 last year[34]. - Cash flow from financing activities generated a net inflow of ¥47,177,286.14, an increase from ¥18,728,322.79 in the prior period[34]. - The company's cash and cash equivalents decreased by 47.05% to ¥162,516,214.68 from ¥306,925,967.42 at the beginning of the period due to investments in financial products[10]. - The company's cash and cash equivalents at the end of the period stood at ¥160,511,201.49, a decrease from ¥165,678,884.60 at the end of the previous period[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,364,012,638.57, an increase of 7.79% from ¥1,264,455,710.99 at the end of the previous year[5]. - The total liabilities increased to RMB 440,932,234.45 from RMB 376,707,118.71 at the beginning of the year[28]. - The company's short-term borrowings increased by 114.25% to ¥43,343,207.59 from ¥20,230,248.24, reflecting an increase in borrowing during the period[10]. - The company's long-term borrowings rose to RMB 74,633,855.38 from RMB 54,254,266.72 at the beginning of the year[28]. - The company's total equity attributable to shareholders increased by 3.80% to ¥887,527,556.22 from ¥855,045,808.43 at the end of the previous year[5]. Operational Costs and Expenses - Operating costs increased by 34.89% to 229,452,106.46 from 170,098,749.76, primarily due to increased revenue[13]. - Sales expenses rose by 35.50% to 30,824,217.84, attributed to business expansion and increased personnel costs[13]. - Research and development expenses were ¥36,540,647.19, up 23.4% from ¥29,623,613.17 year-over-year[31]. - Other income increased by 38.19% to 11,419,778.17, mainly due to higher government subsidies related to daily operations[13]. - Investment income decreased by 40.89% to 990,335.62, primarily due to reduced financial management returns[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,032[17]. - The largest shareholder, Gan Tingchun, holds 28.89% of shares, totaling 106,914,769, with 14,350,000 shares pledged[17]. - The company's minority shareholder profit increased by 85.10% to 1,824,551.70, reflecting higher net profit from the holding company[13]. - The company distributed a cash dividend of RMB 0.1 per 10 shares to all shareholders, completed on July 11, 2023[22]. Research and Development - The company received a patent for a traditional Chinese medicine composition aimed at treating pneumonia, enhancing its R&D capabilities[24]. - The company plans to adjust its fundraising target from a maximum of RMB 84 million to RMB 82.67 million for a specific stock issuance[23]. Inventory and Other Assets - The company’s inventory increased to RMB 220,434,930.36 from RMB 168,362,996.60 at the beginning of the year[27]. - Deferred tax assets increased from 33,599,225.71 to 34,576,543.97, a change of 977,318.26[35]. - Deferred tax liabilities rose from 5,234,735.73 to 6,204,074.63, an increase of 969,338.90[35]. - Unappropriated profits slightly increased from 167,464,079.23 to 167,472,058.59, a change of 7,979.36[35]. Business Growth - The company achieved a new business contract amount of approximately RMB 767 million, representing a year-on-year growth of 46.79%[22].